Back

RNA 5' terminal nucleotide determines the strength of the RIG-I/IFN signaling pathway

Wolczyk, M.; Szymanski, J.; Trus, I.; Naz, Z.; Bolembach, A.; Choudhury, N. R.; Tame, T.; Konuc, C.; Nowak, E.; Spanos, C.; Rappsilber, J.; Michlewski, G.

2023-12-22 molecular biology
10.1101/2023.12.22.573000 bioRxiv
Show abstract

The interferon (IFN) response is crucial for antiviral activity, but its overstimulation can lead to a wide range of autoimmune disorders. The cytoplasmic pattern recognition receptor RIG-I detects viral double-stranded RNAs (dsRNAs) and endogenous polymerase III transcripts carrying a 5'-triphosphate (5'-ppp) or 5'-diphosphate (5'-pp) moiety, triggering phosphorylation of IRF3 and IFN immune response. While many viral RNAs initiate with 5'-ppp-adenosine (5'-pppA) and most endogenous Pol III transcripts in higher eukaryotes start with 5'-ppp-guanosine (5'-pppG), no apparent reason for this bias has been identified so far. Here we demonstrate that dsRNAs initiating with 5'-pppA trigger stronger RIG-I/IFN response than those starting with 5'-pppG. We show that several GTP-binding proteins interact preferentially with 5'-pppG RNAs. Finally, supplementation with guanosine, but not adenosine, which rapidly increases intracellular concentrations of GTP and ATP, respectively, eliminates the difference in immunogenicity between 5'-pppG and 5'-pppA RNAs. Our findings suggest that 5'-pppG RNAs may enable certain RNA viruses and Pol III transcripts to limit detection by innate immune receptors. These results offer new insights into the sequence-dependent activation of the RIG-I/IFN pathway and have important implications for both antiviral immunity and the role of Pol III-derived RNAs in autoimmune diseases.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
RNA Biology
78 papers in training set
Top 0.1%
12.0%
2
Nature Communications
5641 papers in training set
Top 19%
8.9%
3
NAR Molecular Medicine
22 papers in training set
Top 0.1%
7.9%
4
Nucleic Acids Research
1281 papers in training set
Top 3%
7.3%
5
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.1%
6.8%
6
Cell Reports
1498 papers in training set
Top 8%
4.9%
7
Journal of Biological Chemistry
690 papers in training set
Top 2%
4.3%
50% of probability mass above
8
EMBO Reports
263 papers in training set
Top 1%
3.3%
9
RNA
189 papers in training set
Top 0.6%
3.1%
10
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.2%
2.7%
11
Scientific Reports
3612 papers in training set
Top 42%
2.5%
12
iScience
1154 papers in training set
Top 13%
2.1%
13
ACS Chemical Biology
167 papers in training set
Top 1%
1.9%
14
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.3%
1.9%
15
The FEBS Journal
93 papers in training set
Top 0.7%
1.7%
16
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 28%
1.7%
17
Science Advances
1243 papers in training set
Top 21%
1.5%
18
PLOS Pathogens
820 papers in training set
Top 7%
1.4%
19
SLAS Discovery
25 papers in training set
Top 0.2%
1.1%
20
International Journal of Molecular Sciences
494 papers in training set
Top 11%
1.1%
21
Advanced Science
286 papers in training set
Top 7%
1.1%
22
Biochemical Journal
91 papers in training set
Top 1%
1.1%
23
PLOS ONE
5266 papers in training set
Top 57%
1.0%
24
Molecular Cell
350 papers in training set
Top 4%
1.0%
25
Journal of the American Chemical Society
217 papers in training set
Top 2%
0.9%
26
eLife
5828 papers in training set
Top 64%
0.8%
27
Communications Biology
993 papers in training set
Top 29%
0.8%
28
Journal of Virology
499 papers in training set
Top 3%
0.6%
29
Life Science Alliance
285 papers in training set
Top 9%
0.6%
30
Biochemistry
148 papers in training set
Top 3%
0.6%